// App-Quantinova.ai

188 : Real-world data on the use of certolizumab pegol for the treatment of axial spondyloarthritis in clinical practice in Europe: 24-week interim results from a prospective non-interventional cohort study

Researchers

Presenter

  • Nicola Goodson

Principal Investigators

  • Torsten Witte

  • Luc De Clerck

  • Mauro Galeazzi

  • Eduardo Collantes-Estvez

  • Thomas Kumke

  • Xenofon Baraliakos

Medical Centers

  • Institute of Ageing and Chronic Disease, University of Liverpool, UNITED KINGDOM

  • Clinic for Immunology and Rheumatology, Hannover Medical School, Hannover, Germany

  • Rheumatology, Antwerp University Hospital, Antwerp, BELGIUM

  • Rheumatology, University of Siena, Siena, ITALY

  • Rheumatology Department, Hospital Universitario Reina Sofía, Cόrdoba

  • Global Statistical Sciences, UCB Pharma, Monheim, GERMANY

  • Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany

Locations

  • United Kingdom

  • Germany

  • Belgium

  • Italy

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

Biomarkers

  • Cluster of differentiation 95

  • Complement Factor B

Drug/Treatment

  • Certolizumab pegol

Outcome

  • N/A

Study Design

  • Non Interventional

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • NCT02354105

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved